Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as ...
The safety profile is one of the biggest advantages of CAR NK cells, and that is exciting for the field because NK cells do ...
Just weeks after the FDA approved an all-oral regimen for newly diagnosed acute myeloid leukemia (AML), a panel of leukemia ...
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases. The University of Pittsburgh Medical Center (UPMC) faculty have ...
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility ...
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with ...
Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years. Dan Costin, ...
Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies. People living with HIV have historically been excluded from many clinical trials assessing new cancer ...
The phase 2/3 NRG GU002 trial (NCT03070886) evaluated whether adding 6 cycles of docetaxel after radiation and androgen ...
Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen. A frontline PARP inhibitor triplet for ...
Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with ...
Chirag Jain, MBBS, discussed onco-anxiology, a proposed framework for identifying and managing anxiety at each stage of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results